Childrens Mercy Hospital Fellowship Program in Pediatric Pharmacology

描述（由申请人提供）：儿童慈善医院（CMH）通过其儿科临床药理学部门并与杜克大学和费城儿童医院合作，非常适合提供儿科临床/发育药理学领域的全面T32研究奖学金计划。CMH计划在儿科临床药理学，最大的（n=36名成员，其中包括16名全职教师，其中5人已被临床药理学的美国委员会认证）和最富有成效的这样的计划在美国，作为该学科的领先项目之一，已经建立了世界级的声誉。该计划的优秀资源（教师和设施）和丰富的研究环境产生了几个国际公认的卓越研究领域，包括发育药物基因组学，药代动力学，药效学和早期临床试验设计/执行。这一成功的证据反映在NIH对项目教师的持续资助、许多被高度引用的同行评审出版物、为大量博士后学员提供示范性教育/培训（包括受训人员在内共10人;医学博士9人，药学博士1人; 5目前在学术职位），来自不同的背景和不断领导作出科学贡献，通过NICHD-赞助儿科药理学研究单位网络。该项目是美国唯一一个专门致力于儿科临床药理学的项目，已获得美国临床药理学委员会的认可。它最近被采纳为1200万欧元的“示范方案”。GRIP倡议（GRIP倡议），在欧洲范围内开展儿科临床药理学培训。 本T32申请中提出的计划结合了与儿科临床/发育药理学密切相关的学科领域的教学和经验培训（例如，PK、PD、药物基因组学、生物信息学、建模/模拟、药物流行病学、治疗依从性、给药系统、临床试验设计）。所有的教学将由经验丰富的教师（临床和基础科学家）谁在他们的学科领域（S）有显著的研究经验完成。这将通过研究员参与M.S.密苏里州-堪萨斯城医学院提供的生物信息学学位课程。在为期3年的培训期间，所有研究员（与教师导师）将完成基于实验室（翻译），临床（I/II期PK/PD试验）和药物流行病学的研究;所有这些都将产生出版物。他们向独立的过渡将在第三年通过准备K奖赠款申请来促进。最后，CMH的计划包含一个经过验证的，多输入的方法来评估学员和培训师，以及一个全面的方法来招募来自不同专业，文化和种族背景的研究员。长期以来，该计划的卓越记录将为申请人提供儿科临床/发育药理学方面的示范性培训。

DESCRIPTION (provided by applicant): The Children's Mercy Hospital (CMH), through its Division of Pediatric Clinical Pharmacology and with collaboration from both Duke University and the Children's Hospital of Philadelphia, is ideally suited to provide a comprehensive T32 research fellowship program in Pediatric Clinical/Developmental Pharmacology. The CMH program in Pediatric Clinical Pharmacology, the largest (n=36 members which includes 16 full time faculty members, 5 of whom have been certified by the American Board of Clinical Pharmacology) and most productive such program in the U.S., has developed a world-class reputation as one of the leading programs in this discipline. The outstanding resources (both faculty and facilities) and rich research environment of this program has produced several internationally recognized areas of research excellence which include developmental pharmacogenomics, pharmacokinetics, pharmacodynamics, and early phase clinical trial design/execution. Evidence of this success is reflected by sustained funding of program faculty from NIH, numerous highly cited peer-reviewed publications, the provision of exemplary education/training to a large number of postdoctoral trainees (10 total including those in training; 9 MD, 1 PharmD; 5 currently in academic positions) from diverse backgrounds and continuous leadership in making scientific contributions through the NICHD-sponsored Pediatric Pharmacology Research Unit Network. This program is the only one in the U.S. solely dedicated to Pediatric Clinical Pharmacology that has been accredited by the American Board of Clinical Pharmacology. It has been recently adopted as a "model program" for a ,12million E.C. initiative (GRIP initiative) to develop Pediatric Clinical Pharmacology training across Europe. The program proposed in this T32 application combines didactic and experiential training in subject areas germane to Pediatric Clinical/Developmental Pharmacology (e.g., PK, PD, pharmacogenomics, bioinformatics, modeling/simulation, pharmacoepidemiology, treatment adherence, drug delivery systems, clinical trial design). All teaching will be accomplished by experienced faculty (both clinical and basic scientists) who have significant research experience in their subject area(s). This will be augmented by fellow's participation in a M.S. degree program in Bioinformatics offered by the University of Missouri - Kansas City School of Medicine. Over a 3 year total training period, all fellows (with faculty mentors) will complete an investigation that is laboratory-based (translational), clinical-based (phase I/II PK/PD trial) and pharmacoepidemiology-based; all of which will produce a publication. Their transition to independence will be fostered in the 3rd year by preparation of a K-award grant application. Finally, the program at CMH contains a proven, multiple-input method for evaluation of trainees and trainers, and a comprehensive approach for recruiting fellows from diverse professional, cultural and ethnic backgrounds. The longstanding, documented record of excellence of this program will provide applicants with exemplary training in Pediatric Clinical/Developmental Pharmacology.